Takeda (ADR) (TAK)
Develops prescription medicines across gastrointestinal disease, rare disease, plasma therapies, oncology, neuroscience, and vaccines.
$18.89
After hours−0.06 (−0.34%)
At close$18.96(+0.34%)
In millions of USD, except per-share figures · converted from JPY at the latest rate
| In millions | Q2 FY23Sep 2023 | Q3 FY23Dec 2023 | Q4 FY23Mar 2024 | Q1 FY24Jun 2024 | Q2 FY24Sep 2024 | Q3 FY24Dec 2024 | Q4 FY24Mar 2025 | Q1 FY25Jun 2025 | Q2 FY25Sep 2025 | Q3 FY25Dec 2025 | Q4 FY25Mar 2026 | Q1 FY26Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 6,628 | 7,061 | 6,678 | 7,676 | 7,473 | 7,270 | 6,694 | 7,032 | 7,071 | 7,709 | 7,083 | 7,752 |
| Cost of revenue | 2,183 | 2,411 | 2,461 | 2,459 | 2,506 | 2,649 | 2,428 | 2,444 | 2,415 | 3,513 | 3,627 | 2,584 |
| Gross profit | 4,445 | 4,650 | 4,216 | 5,217 | 4,968 | 4,621 | 4,266 | 4,588 | 4,656 | 4,196 | 3,456 | 5,168 |
| 4,759 | 3,983 | 4,280 | 4,160 | 3,797 | 4,196 | 4,742 | 3,415 | 4,218 | 2,963 | 3,154 | 3,888 | |
| Research & development | 1,169 | 1,191 | 1,245 | 1,071 | 1,116 | 1,081 | 1,373 | 914 | 1,026 | 1,134 | 1,264 | 1,064 |
| Selling, general & administrative | 1,607 | 1,700 | 1,813 | 1,716 | 1,705 | 1,719 | 1,880 | 1,626 | 1,611 | 1,829 | 1,890 | 1,821 |
| Other expenses | 1,982 | 1,092 | 1,223 | 1,374 | 976 | 1,395 | 1,489 | 875 | 1,580 | 0 | 0 | 1,003 |
| Operating income | −314 | 667 | −64 | 1,057 | 1,171 | 425 | −476 | 1,173 | 438 | 1,233 | 302 | 1,280 |
| −296 | −277 | −238 | −189 | −412 | −258 | −206 | −216 | −259 | −367 | −642 | −246 | |
| Interest income | 0 | 138 | 0 | 195 | 26 | 0 | 1 | 469 | 282 | 568 | 33 | 156 |
| Interest expense | 3 | 423 | 2 | 379 | 435 | 1 | 2 | 681 | 528 | 800 | 282 | 406 |
| Other non-operating income | −72 | 222 | −1,055 | −190 | −23 | 387 | −422 | −465 | −269 | −433 | 359 | −160 |
| Income before tax | −610 | 389 | −302 | 868 | 759 | 168 | −682 | 957 | 179 | 866 | −340 | 1,034 |
| Income tax expense | −305 | −283 | −283 | 262 | 173 | 16 | −27 | 167 | 254 | 195 | −183 | 314 |
| Net income from continuing operations | −305 | 672 | −19 | 606 | 585 | 151 | −655 | 790 | −75 | 671 | −157 | 720 |
| Discontinued operations | 0 | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other adjustments | 0 | 0 | 0 | 0 | −3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income | −305 | 672 | −19 | 605 | 585 | 151 | −656 | 790 | −75 | 670 | −157 | 719 |
| EPS, basic | −$0.10 | $0.21 | −$0.01 | $0.19 | $0.18 | $0.05 | −$0.21 | $0.25 | −$0.02 | $0.21 | −$0.05 | $0.23 |
| EPS, diluted | −$0.10 | $0.21 | −$0.01 | $0.19 | $0.18 | $0.05 | −$0.21 | $0.25 | −$0.02 | $0.21 | −$0.05 | $0.22 |
| Weighted average shares, basic | 3,131 | 3,138 | 3,137 | 3,138 | 3,166 | 3,170 | 3,163 | 3,129 | 3,155 | 3,159 | 3,125 | 3,160 |
| Weighted average shares, diluted | 3,131 | 3,170 | 3,137 | 3,178 | 3,220 | 3,170 | 3,163 | 3,176 | 3,155 | 3,205 | 3,125 | 3,209 |
| EBITDA | 1,285 | 1,633 | 1,647 | 2,469 | 2,416 | 1,226 | 1,152 | 2,792 | 2,011 | 2,899 | 1,003 | 2,145 |
| Depreciation & amortization | 1,527 | 1,189 | 656 | 1,221 | 1,223 | 1,188 | 1,206 | 1,154 | 1,304 | 1,233 | 1,060 | 705 |
| EBIT | −241 | 445 | 992 | 1,247 | 1,194 | 38 | −54 | 1,638 | 707 | 1,666 | −57 | 1,440 |